 
  
Natural History of Infection Caused by [CONTACT_171888] (and other Opportunistic Viral 
Pathogens) in Renal and Renal-Pa ncreas Transplant Recipi[INVESTIGATOR_171863]:  11-0071  
 
DMID Funding Mechanism: HHSN272201100036C 
 
Sponsor:   National Institutes of Health/NIAID  
 
Principal Inve stigator:  Richard J. Whitley, MD 
 University of Alabama at Birmingham  
 
DMID COR:  Walla Dempsey, PhD 
NIH/NIAID  
 
Protocol Chair:   
John W. Gnann, Jr., MD 
Medical University of South Carolina 
 
Protocol Statistician: 
Inmaculada B. Aban, PhD 
University of Alabama at Birmingham 
 
UAB Central Unit Administration:  
Penelope M. Jest er, BSN, MPH 
Ilet Dale, BSN, MSc.M, CCRP 
University of Alabama at Birmingham 
 
Version Number : 2.[ADDRESS_201666] met protocol eligibility criteria.  This study will be conducted in compliance with the protocol and in accordance with Good Clinical 
Practices (GC) as required by [CONTACT_716]:   
 
 International Conference on Harmonization Good Clinical Practice E6 (ICH-E6 GCP) and the 
following applicable regulatory requirements: 
  U.S. Code of Federal Regulators applicable to clinical studies (45 CFR 46 and 21 CFR 11 
including parts 50 and 56 concerning informed consent and IRB regulations). 
  NIH Terms of Award 
 
All key personnel (all individuals responsible for the design and conduct of this study) have completed 
Human Subjects Protection Training.  
 
 
                   DMID Protocol 11-0071, Version 2.[ADDRESS_201667] this protocol  
“Natural History of Infection Caused by [CONTACT_171888] (and other Opportunistic Viral Pathogens) in 
Renal and Renal-Pancreas Transplant Recipi[INVESTIGATOR_840]” and provide the necessary assurances that this 
study  will be conducted according to all stipulations of the protocol, including all statements regarding 
confidentiality, and according to local legal and regulatory requirements and applicable U.S. federal 
regulations and ICH guidelines.  I understand that no deviations from the protocol may be made 
without permission of the sponsor.  I also understand that information in this protocol is proprietary and therefore, I agree to maintain the confidentiality of the protocol and data generated from the protocol 
until permission to publicize results is granted by [CONTACT_18121].   
 
 
 
SITE PRINCIPAL INVESTIGATOR:   
 
 
________________________________________  _______________   Signature  [CONTACT_1782] 
  _______________________________________ 
Title 
                   DMID Protocol 11-0071, Version 2.[ADDRESS_201668] OF ABBREVIATIONS  ..............................................................................................................................................  VII 
PROTOCOL  SUMMARY  ..................................................................................................................................................  IX 
SCHEMATIC  OF STUDY DESIGN ......................................................................................................................................  XI 
1.  KEY ROLES ................................................................................................................................................................  12 
2.  BACKGROUND  INFORMATION  AND SCIENTIFIC  RATIONALE  ......................................................................................  15 
2.1.  BACKGROUND  INFORMATION  ..............................................................................................................................................  15 
2.1.1.  BK Virus (BKV) and  BKV‐Associated  Nephropathy  (BKVN)  ..................................................................................  15 
2.2.  SCIENTIFIC  RATIONALE .......................................................................................................................................................  17 
2.2.1.  Renal (or Renal‐Pancreas  Transplant)  Patients ...................................................................................................  17 
2.3.  POTENTIAL  RISKS AND  BENEFITS ..........................................................................................................................................  17 
2.3.1  Potential  Risks ......................................................................................................................................................  17 
2.3.2.  Potential  Benefits ................................................................................................................................................  17 
3.  OBJECTIVES  ..............................................................................................................................................................  18 
3.1.  STUDY  OBJECTIVES ...........................................................................................................................................................  18 
3.1.1.  Primary Objectives  ...............................................................................................................................................  18 
3.1.2.  Secondary  Objectives  ...........................................................................................................................................  18 
3.1.3.  Tertiary (Exploratory)  Objectives  .........................................................................................................................  [ADDRESS_201669]‐VIREMIA FOLLOW‐UP ...............................................................................................................................................  23 
4.5.  SPECIMENS  FOR BIOMARKER  STUDIES ...................................................................................................................................  23 
4.6.  DOCUMENTING  SPECIAL  EVENTS .........................................................................................................................................  23 
4.7.  ADVERSE EVENTS .............................................................................................................................................................  24 
4.8.  CLINICAL LABORATORY  DATA ..............................................................................................................................................  24 
4.9.  STUDY  VISITS ...................................................................................................................................................................  24 
5.  STUDY POPULATION  ................................................................................................................................................  25 
5.1.  STUDY  POPULATION  SELECTION ...........................................................................................................................................  25 
5.2.  INCLUSION  OF WOMEN , CHILDREN AND  MINORITIES ...............................................................................................................  25 
5.3.  INCLUSION /EXCLUSION  CRITERIA .........................................................................................................................................  25 
                   DMID Protocol 11-0071, Version 2.0 
BK Natural History                     22 March 2016 
 
________________________________________________________________________________________________________ 
v 
 
 5.3.1.  Inclusion  Criteria ..................................................................................................................................................  25 
5.3.2.  Exclusion Criteria .................................................................................................................................................  25 
6.0.   SCHEDULE  OF EVENTS ...........................................................................................................................................  26 
6.1.  ENROLLMENT  VISIT  (DAY 1) ...............................................................................................................................................  [ADDRESS_201670] WITHDRAWALS  ..........................................................................................................................  29 
6.6.  TERMINATION OF  STUDY ....................................................................................................................................................  29 
7.0.   STUDY PROCEDURES  .............................................................................................................................................  30 
7.1.  DEMOGRAPHICS , BASELINE  MEDICAL‐SURGICAL  HISTORY , CLINICAL OUTCOMES ..........................................................................  30 
7.2.  LABORATORY  – SPECIMEN  COLLECTION ............................................................................................................................... . 30 
7.2.1.  At Each Screening  Visit: .......................................................................................................................................  30 
7.2.2.  At Each Intensive Follow‐ up Visit for Viremic Subjects: .......................................................................................  30 
7.3.  REPORTING  OF CONCOMITANT  MEDICATIONS  ........................................................................................................................  31 
7.4.  DOSING OF  IMMUNOSUPPRESSIVE  DRUGS .............................................................................................................................  31 
7.5.  MEASUREMENT  OF VIRAL DNA...........................................................................................................................................  31 
7.6.  SPECIMEN  PREPARATION , HANDLING  AND  SHIPPI[INVESTIGATOR_1645] ...............................................................................................................  32 
8.  STATISTICAL  CONSIDER ATIONS................................................................................................................. ................  33 
8.1.  STUDY  HYPOTHESIS ...........................................................................................................................................................  33 
8.2.  SAMPLE SIZE CONSIDERATIONS  ...........................................................................................................................................  33 
8.2.1.  Sample Size ..........................................................................................................................................................  33 
8.2.2.  Estimated  Annual Accrual ...................................................................................................................................  34 
8.3.  DEMOGRAPHIC  ANALYSIS ...................................................................................................................................................  34 
8.4.  FINAL ANALYSIS PLAN........................................................................................................................................................  35 
8.4.1.  Primary Outcome Analysis ...................................................................................................................................  35 
8.4.2.  Secondary  Endpoints  ...........................................................................................................................................  36 
8.4.3.  Exploratory  Endpoints  .........................................................................................................................................  36 
9.  SOURCE DOCUMENTS  AND ACCESS  TO SOURCE DATA/ DOCUMENTS  .......................................................................  [ADDRESS_201671] .........................................................................................................................................  39 
11.3.  INFORMED  CONSENT PROCESS ..........................................................................................................................................  39 
11.4.  EXCLUSION  OF WOMEN , MINORITIES , AND  CHILDREN (SPECIAL POPULATIONS ) ..........................................................................  [ADDRESS_201672] KEEPI[INVESTIGATOR_1645] ................................................................................................................  43 
12.1  DATA CAPTURE METHODS ................................................................................................................................................  43 
                   DMID Protocol 11-0071, Version 2.0 
BK Natural History                     22 March 2016 
 
________________________________________________________________________________________________________ 
vi 
 
 12.2  TYPES OF  DATA ...............................................................................................................................................................  44 
12.3  TIMING /REPORTS ............................................................................................................................................................  [ADDRESS_201673] Aspartate Aminotransferase  
AUC Area Under the Curve  
BKC 
BKV BK Cystitis  
BK Virus  
BKVN  BK Virus-Associated Nephropathy  
BLQ Below the Limit of Quantitation  
BMI Body Mass Index  
BP Blood Pressure  
CDC Centers for Disease Control  
Cº Celsius/Centigrade  
Cmax Maximum Concentration  
CFR Code of Federal Regulations  
CLT Total Clearance  
CMV Cytomegalovirus  
CrCl Creatinine Clearance  
CRF Case Report Form  
DMID  Division of Microbiology and Infectious Diseases  
DNA Deoxyribonucleic Acid  
EBV Epstein Barr Virus  
eCRF  Electronic Case Report Form  
FDA U.S. Food and Drug Administration  
FK506  Tacrolimus  
FWA Federal wide Assurance  
GCP Good Clinical Practice  
GI Gastrointestinal  
GFR Glomerular Filtration Rate
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
HHV-[ADDRESS_201674]  
IVIS Intravenous Immunosuppressant  
kg Kilograms  
mg Milligrams  
ml Milliliters  
min Minute  
MMF Mycophenolate Mofetil  
MOP  Manual of Procedures  
N Number (typi[INVESTIGATOR_19737])  
NIAID  National Institute of Allergy and Infectious Diseases Number  
NIH National Institutes of Health  
PCR Polymerase Chain Reaction  
PI [INVESTIGATOR_171864]•BKV DNAPI  [INVESTIGATOR_171865]  
T Temperature  
Tmax Maximum Time  
Tmax Maximum Time  
µg Microgram  
ur•BKV DNA  Urine levels of BKV DNA  
µL Microliter  
ur•BKV DNA  Urine levels of BKV DNA  
UTI Infection  
WBC  White Blood Cells  
WHO  World Health Organization  
 
  
                   DMID Protocol 11-0071, Version 2.0 
BK Natural History                     22 March 2016 
 
________________________________________________________________________________________________________ 
ix 
 
 PROTOCOL SUMMARY 
 
Title:  Natural History of Infection Caused by [CONTACT_171888] (and other Opportunistic 
Viral Pathogens) in Renal and Renal-Pancreas Transplant Recipi[INVESTIGATOR_171866]:  Not Applicable (Natural History Study) 
Study Population:  Male and female renal or renal-pancreas transplant recipi[INVESTIGATOR_171867]:  Approximately 450 subjects will be enrolled for screening for BK viremia 
(15% over-enrollment allowed, to a maximum of 518 screened subjects) 
to allow identification of approximately 40 (to a maximum of 60) subjects 
with viremia.     
Number of Sites:    Approximately  6
Study Duration:    [ADDRESS_201675] Participation  
Duration:   Maximum of 24 months 
Objectives: 
 Primary Objectives:  
 To establish the natural history of BK viremia in a multicenter 
population of renal and renal/pancreas transplant patients, to include incidence, time to onset, duration, and quantitation of viral load; 
 To assess associations between BK viremia and decline in GFR in 
renal transplant recipi[INVESTIGATOR_840]. 
 
Secondary Objectives:  
 To define the donor and recipi[INVESTIGATOR_841]-related risk factors for BK viremia 
and BKVN in a multicenter population of renal and renal-pancreas transplant patients; 
 To define the frequency of clinical outcomes that are potentially 
related to BKV infection. 
Tertiary (Exploratory) Objectives:
 
 To compare quantitative measurements of BKV DNA by [CONTACT_171889] (when appropriate) in urine, in order to determine 
biologic significance; 
 To assess plasma for evidence of other opportunistic viral pathogens, 
including CMV, EBV, HHV-6, and adenovirus; 
 To assess urine for evidence of other opportunistic viral pathogens, 
including CMV and adenovirus; 
                   DMID Protocol 11-0071, Version 2.0 
BK Natural History                     22 March 2016 
 
________________________________________________________________________________________________________ 
x 
 
  To compare quantitative BKV PCR results from each site (local or 
reference laboratory) with matched results from the Central Unit 
laboratory;  
 To explore the potential of biomarkers of tubular injury for predicting 
increased risk of BKVN; 
 
Description of Study 
Design: The primary objective is to define the natural history of BK viremia. In 
order to understand the natural history of infection, we will measure the 
time (days post-transplant) to the development of BK viremia and its 
correlation with progression to end-organ disease (BKVN or BK 
hemorrhagic cystitis). Data from this prospective monitoring will allow for the identification of the types of high-risk patients who might benefit from 
future studies of therapeutic interventions for BKV infection (when 
effective therapy becomes available).  This will be accomplished by [CONTACT_171890] (plasma), assayed by [CONTACT_940] (PCR).  Phases of the study can be 
summarized as follows:
 
 Subject identification and informed consent.  Informed consent 
should be obtained early in the peri-transplant period (between 7 
days pre-transplantation [T-7d] and [ADDRESS_201676]- transplantation 
[T+100 d]).  
 Prospective screening for BK viremia.  Enrollment and initiation of 
specimen collection should begin no sooner than 4 weeks after transplantation.  Enrollment cannot occur later than 100 days after transplantation.  Subjects will be screened (collection of blood and urine for laboratory studies, including BK PCR) approximately 
monthly for 6 months (timed from the date of transplantation), then 
every other month for 6 months. For those subjects who remain BKV-negative, screening will terminate appr oximately 12 months from the 
date of transplantation.
 
 Intensive sampling of subjects identified with BK viremia.  Subjects 
identified with qualifying viremia will be sampled approximately every 
two weeks until resolution of viremia (defined as PCR negative, or 
<1000 copi[INVESTIGATOR_014]/ml).  
Note:  Patients who did not participate in the prospective screening 
phase but are identified with BK viremia by [CONTACT_38183]-of-care testing 
may be enrolled, as long as they are still within 100 days of transplantation. 
 Post-viremia follow-up.  Following resolution of viremia, subjects will 
be sampled (collection of blood and urine) approximately monthly for 6 months (unless another termination event occurs sooner).
 
 
 
                       DMID Protocol 11-0071, Version 2.0 
B K  N a t u r a l  H i s t o r y                2 2  M a r c h  2 0 1 6  
 
 
 
________________________________________________________________________________________________________________________________________________ 
  xi  
 
 
 SCHEMATIC OF STUDY DESIGN 
 
DMID Protocol # 11-0071 Active Screening/Natural History Phase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 Initiate recruitment and informed consent 
process in the peri-transplant period (T-7 d 
through T+100 d) 
 Collect approx. 10 mL of whole blood and 100 mL urine every 4 weeks ±7 days 
x 6 months (as measured from date of transplant). 
 Process whole blood to plasma; ship plasma to UAB Central Lab for BKV PCR 
within 7 days of collection.   
 Urine will be stored and batch-shipped to UAB Central Lab monthly. 
 Enrollment visit for consented subjects not <[ADDRESS_201677]- 
transplant and not >[ADDRESS_201678]-transplantation 
 
 Record demographic, medi cal-surgical history at 
enrollment 
 Record selected concomitant medications, drug levels, at each visit. 
If no BK viremia detected by [ADDRESS_201679]-transplant, switch to blood and urine samples collection 
approximately every 8 weeks + [ADDRESS_201680] will be discontinued from the study If qualifying BK viremia (>10,000 copi[INVESTIGATOR_014]/ml) is documented, do the 
following: 
 Plasma and urine samples are collected approximately every 2 
weeks ± 7 days until viremia has resolved (or until patient meets one of the study termination outcomes). 
After resolution of BK viremia, do the following: 
 plasma and urine samples are collected approximately every 4 
weeks X 6 months (or until subject meets one of the study 
termin ation outco mes). 
                 
                            DMID Protocol 11-0071, Version 2.[ADDRESS_201681]: 
 
  DMID COR:   
Walla Dempsey, PhD Division of Virology DMID/NIAID/NIH  
Division of Microbiology and Infectious Diseases, NIAID, NIH  
Room [ADDRESS_201682], MSC 6604  
Bethesda, MD  [ZIP_CODE] (Zip for express mail is [ZIP_CODE])  
Phone:  [PHONE_3719]  
FAX:   [PHONE_3720]  
e-mail:  [EMAIL_2259]  
 
Principal Investigator:  
[CONTACT_24617] J. Whitley, MD  
Distinguished [CONTACT_171915] in Pediatrics  
Professor of Pediatrics, Microbiology,  
   Medicine, and Neurosurgery  
The University of Alabama at Birmingham [ADDRESS_201683] South, CHB 303 Birmingham, AL  [ZIP_CODE] 
Phone: [PHONE_2597] 
Fax:   [PHONE_3721] e-mail:  [EMAIL_3421]
 
 
 
 Protocol Chair:    
John W. Gnann, Jr., MD  
Professor of Medicine  
Department of Medicine, Division of Infectious Diseases  
Medical University of South Carolina  
[ADDRESS_201684], Room 1207  
MSC 752  
Charleston, SC   [ZIP_CODE]  
Telephone:  [PHONE_3722]  
Fax:             [PHONE_3723]  
e-mail:  [EMAIL_3422]  
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
13 
   
 Program Director: 
Penny Jester BSN MPH CCRC  
UAB Central Unit 
The University of Alabama at Birmingham 
[ADDRESS_201685] South, CHB 303 Birmingham, AL  [ZIP_CODE] 
Phone:  [PHONE_2597] 
Fax:   [PHONE_3721] e-mail:  [EMAIL_2261]   
 
 Clinical Trials Administrator Ilet Dale, BSN, MSc.M, CCRP 
UAB Central Unit
 
The University of Alabama at Birmingham  
[ADDRESS_201686] South, CHB 303  
Birmingham, AL  [ZIP_CODE]  
Phone:  [PHONE_2597]  
FAX:   [PHONE_3721]  
e-mail:  [EMAIL_3423]   
 Statistician: 
Inmaculada "Chichi" Aban, PhD  
Associate [CONTACT_10139] of Biostatistics School of Public Health 
The University of Alabama at Birmingham 
RPHB 327 Phone:  [PHONE_3724] 
Fax:      [PHONE_3725] 
e-mail:  [EMAIL_3424] 
 
 
 
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
14 
  Investigators/Institutions : 
 
Roslyn B. Mannon University of Alabama at Birmingham 
David J Cohen, MD Columbia University Medical Center 
Daniel Brennan, MD Washington University-St. Louis 
JoAnne Young, MD University of Minnesota 
Alexander C. Wiseman, MD University of Colorado-Denver 
V.Ram Peddi, MD [LOCATION_004] Pacific Medical Center 
 
 
  
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
15 
 2.  BACKGROUND INFORMATIO N AND SCIENTIFIC RATIONALE 
 
2.1.  Background Information 
 
2.1.1.  BK Virus (BKV) and BKV-Associated Nephropathy (BKVN) 
 BK virus (BKV) is a small (45 to 55 nm) non-enveloped polyoma virus, having a circular double-
stranded DNA (dsDNA) genome with approximately 5,[ADDRESS_201687] isolated in 
1970 from a renal transplant patient (initials “BK”) with ureteral stenosis.  Seroepi[INVESTIGATOR_171868].  In a healthy Swiss cohort aged 20-59 years, the 
seroprevalence for BKV was 82%.
[ADDRESS_201688].  
BKV rarely causes disease in immunocompetent adults, but in the setting of immunosuppression 
(such as renal transplantation) BKV can reactivate  and cause asymptomatic viruria or symptomatic 
disease.  The donor kidney also appears to be an important source of BKV infection in the graft recipi[INVESTIGATOR_841].  Studies have shown that the higher th e BKV antibody titer in the donor, the greater the 
incidence of BKV disease in the renal transplant recipi[INVESTIGATOR_841].
2  BKV nephropathy (BKVN) and ureteral 
stenosis are the most commonly described clinical manifestations of BKV infection in renal transplant recipi[INVESTIGATOR_840].
[ADDRESS_201689] often in hematopoietic stem cell transplant (HSCT) patients, but occurs in renal 
transplant patients as well.   
 
Studies of the natural history of BKV infection have been greatly facilitated  by [CONTACT_171891].4  Approximately 30 to 60% of all renal transplant recipi[INVESTIGATOR_171869].5-7  Approximately 10 to 15% of all renal 
transplant recipi[INVESTIGATOR_171870] (preceded in most cases by [CONTACT_171892]).5, [ADDRESS_201690] only by a 
progressive increase in serum creatinine.  Histopathologic examination of the renal allograft has 
traditionally been the “gold standard” for the definitiv e diagnosis of BKVN.  However, recent studies 
have demonstrated that BKV DNA can be readily detected in blood using polymerase chain 
reaction (PCR) methodology in virtually all patients with histologically proven BKVN.  Indeed, BKV 
DNA can often be detected in blood or urine for several months prior to the development of renal 
dysfunction, presenting an opportunity for therapeut ic intervention.  Although BKVN was first 
reported in 1978, dramatic increases in the incidence of the syndrome were noted after the 
                 
                            DMID Protocol 11-0071, Version 2.[ADDRESS_201691] reported rates of BKVN 
ranging from 1 to 10%.12-14 One prospective study reported an 8% incidence of BKVN in renal 
transplant patients who received one or more of the newer immunosuppressive agents, such as 
tacrolimus, mycophenolate mofetil, and sirolimus.[ADDRESS_201692], BKVN has been seen much more commonly in the era of more potent immunosuppressive agents; most patients with documented BKVN have received one or more of these newer 
immunosuppressive drugs.  Second, some patients with BKVN appear to clear virus from the blood 
and urine after reduction of the intensity of immunosuppressive therapy.
[ADDRESS_201693] infection of allograft renal tubular epi[INVESTIGATOR_1663] (TECs).  Molecular analysis has demonstrated that there is substantial inflammatory injury 
associated with a profibrotic milieu.
[ADDRESS_201694] of care is early screening for BKV viremia and reduction in immunosuppressive therapy in an effort to improv e graft survival, although it has not been studied 
in a controlled fashion.
12,18,19 At some institutions, modulation of immunosuppressive therapy has 
dramatically reduced the rate of allograft loss due to BKVN.14 Reduction in the immunosuppressive 
regimen is not without consequence and can resu lt in graft loss from immune-mediated organ 
rejection.20  Despi[INVESTIGATOR_171871], in some studies 30 to 70% of patients with 
BKVN have progressive deterioration in renal func tion, eventually resulting in allograft loss.  
Declining renal function typi[INVESTIGATOR_171872] a combination of persistent viral infection, organ rejection (induced by [CONTACT_171893]), and renal 
fibrosis.   
 This study is being performed to identify the natural history of BK viremia in renal transplant 
patients with the intent to identify high-risk groups that may benefit in the future from therapy with 
                 
                            DMID Protocol 11-0071, Version 2.[ADDRESS_201695] 
been selected for inclusion in this study as they are an at-risk patient population with an unmet medical need.    
2.2.1.  Renal (or Renal-Pancreas Transplant) Patients   
 
Approximately 30 – 60% of all renal or renal-p ancreas transplant patients will have detectable 
levels of BKV DNA in their urine in the post-tran splant period.  Approximately 10 – 15% of renal 
transplant patients will have BK viremia.  Among the patients who progress to BKVN, virtually all 
will have BK viremia. Predictors of viremia inclu de early onset of BK viruria, rapid increase in 
quantitative viruria, and high peak titers of BKV DNA in urine.  In an effort to capture these subjects early in the course of the evolving BK infection and avoid subjects who have already developed evidence of BKVN, this protocol will emphasize t he initiation of screening in the early post-
transplant period. In addition, since BKVN tends to occur most frequently within the first six months after transplantation, screening will be more frequent early in the post-transplant period.  
2.3.  Potential Risks and Benefits 
 
2.3.[ADDRESS_201696] data and specimens can be timed for collection at the participants’ standard-of-care clinic visits. There are no potential benefits for an individual volunteering to take part in this 
natural history study, other than contributing to a better understanding of an infectious disease for 
which he/she is at risk. The participant will be allowing the research to collect data and residual blood samples that can be used to research BK infection and provide potentially useful data for 
monitoring and treatment of future transplant patients. 
 
2.3.2.  Potential Benefits 
 There may not be any direct benefit for individual subjects enrolled in this study.  Some study specimens will be batch-shipped and processed, so results will not always be available to inform  
the subjects’ clinical management.  Indirectly, the data from this study will teach the transplant 
community when interventions are most likely to be successful. 
  
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
18 
 3.  OBJECTIVES 
 
3.1.  Study Objectives 
 
3.1.1.  Primary Objectives  
 To establish the natural history of BK viremia in a multicenter population of renal and 
renal/pancreas transplant patients, to include incidence, time to onset, duration, and 
quantitation of viral load; 
 To assess associations between BK viremia and decline in GFR in renal transplant recipi[INVESTIGATOR_840]. 
 
3.1.2.  Secondary Objectives 
  
 To define the donor and recipi[INVESTIGATOR_841]-related risk factors for BK viremia and BKVN in a multicenter 
population of renal and renal-pancreas transplant patients; 
 To define the frequency of clinical outcomes that are potentially related to BKV infection. 
 
3.1.3.  Tertiary (Exploratory) Objectives 
 
 To compare quantitative measurements of BKV DNA by [CONTACT_171894], when 
appropriate, in urine, in order to determine biologic significance; 
 To assess plasma for evidence of other opportunistic viral pathogens, including CMV, EBV, 
HHV-6, and adenovirus; 
 To assess urine for evidence of other opportunistic viral pathogens, including CMV and 
adenovirus; 
 To compare quantitative BKV PCR results from each site (local or reference laboratory) with 
matched results from the Central Unit laboratory;  
 To explore the potential of biomarkers of tubular injury for predicting increased risk of BKVN. 
 Relationship of development of BKVN with immunosuppressive therapy 
 
 
3.2.  Study Outcome Measures  
3.2.1.  Primary Endpoints 
 
 Incidence of BV viremia in the study population of screened renal or renal/pancreas transplant 
subjects.  
 
3.2.2.  Secondary endpoints 
 
 Timing of onset of BK viremia (number of days post-transplant) 
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
19 
  Duration of BK viremia 
 Incidence of BKVN in the study population 
 Dynamics of quantitative measurements of BK viremia over time 
 Frequency of donor and recipi[INVESTIGATOR_841]-related risk factors for BV viremia, including: 
a. Donor-derived factors:  
i. Deceased donor – Standard criteria donor (SCD), Donor after cardiac death 
(DCD), Expanded criteria donor (ECD) 
ii. Living donor – related donor or unrelated donor 
iii. ABO incompatibility  
iv. Total HLA mismatches 
v. HLA C7 status  
vi. Race/ethnicity 
vii. Sex 
b. Recipi[INVESTIGATOR_841]-derived factors:  
i. Delayed graft function (DGF), defined as use of dialysis within 7 days of the 
transplant  
ii. Cold ischemia time (CIT) 
iii. Warm ischemia time (WIT)  
iv. Use of stents  
v. HLA C7 status 
vi. Type/intensity of immunosuppression, including corticosteroids 
vii. Acute rejection  
viii. Age 
ix. Race/ethnicity  
x. Sex 
 
 Frequency of clinical outcomes that are potentially related to BKV infection, including:  
a. subject death, 
b. loss of graft function as defined by [CONTACT_171895] <10 mL/min/1.73 m2 
c. development of urinary outlet obstruction 
d. development of gross hematuria e. development of lymphocele  
f. acute rejection 
g. initiation of dialysis h. re-transplantation 
i. renal biopsies  
 
 
3.2.3.  Exploratory Endpoints 
 
 Frequency of BK viruria (incidence, time of onse t, duration, viral load quantitation by [CONTACT_954]) in 
subjects with and without BK viremia 
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
20 
  Frequency of CMV, EBV, HHV-6, and adenovirus viremia at multiple time points in subjects 
with and without BK viremia 
 Frequency of CMV and adenovirus viruria at multiple time points in subjects with and without 
BK viremia 
 Results of BK PCR assays performed on matched specimens at the participating sites (local or 
reference laboratories) and at the UAB Central Laboratory 
 Results of urinary biomarkers of tubular injury measured at multiple time points in subjects with 
and without viremia, including any subjects with BKVN.  Potential urinary biomarkers include 
cystatin C, renin, clusterin, Kim-1, b2-microglobulin, osteopontin, retinol binding protein, and markers of cell apoptosis. Urine biomarkers will not be resulted in real-time.  
  
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
21 
 4.  STUDY DESIGN  
The primary objective is to define the natural history of BK viremia in renal or renal-pancreas 
transplant recipi[INVESTIGATOR_840].   In order to understand the natural history of infection, we will measure the 
time to the development of BK viremia and its correlation with progression to end-organ disease 
(BKVN or BK hemorrhagic cystitis). Data from th is intensive natural history monitoring period will 
allow for the identification of the types of high-risk patients who might benefit from future studies of therapeutic interventions for BKV infection, when e ffective therapy becomes available.  This will be 
accomplished by [CONTACT_171896] (plasma).  It is anticipated that most samples (blood and urine) will be collected during routine standard-of-care clinic visits and will not require extra study visits. Phases of the study can be summarized as 
follows: 
 
 Subject identification and informed consent.  Informed consent should be obtained in the 
peri-transplant period (between 7 days pre-transplantation [T-7d] and [ADDRESS_201697]- transplantation [T+100 d]).
 
 Prospective screening for BK viremia.  Enrollment and initiation of specimen collection 
should begin no sooner than 4 weeks after transplantation.  Enrollment cannot occur later than 100 days after transplantation.  Subjects will be screened (collection of blood and 
urine for laboratory studies, including BK PC R) approximately monthly for 6 months (timed 
from the date of transplantation), then every other month for 6 months. For subjects who 
remain BKV-negative, screening will terminate approximately 12 months from the date of 
transplantation.
 
 Intensive sampling of subjects identified with BK viremia.  Subjects identified with qualifying 
viremia will be sampled approximately every two weeks until resolution of viremia (defined 
as PCR negative, or <1000 copi[INVESTIGATOR_014]).  
Note:  Patients who did not participate in the prospective screening phase but are identified with BK viremia by [CONTACT_38183]-of-care testing may be enrolled, as long as they are still within 90 days of transplantation. 
 Post-viremia follow-up.  Following resolution of viremia, subjects will be sampled (collection 
of blood and urine) approximately monthly for 6 months (unless another termination event occurs sooner).
 
 
4.1.  Informed Consent and Enrollment 
In an effort to capture subjects early in the course of the evolving BK infection and to avoid 
subjects who have already devel oped evidence of BKV-induced nephropathy (BKVN), this protocol 
will emphasize the natural history of early-onset BK viremia. Obtaining informed consent early in the peri-transplant period is encouraged, although enrollment and study-related specimen 
collections will not begin until >[ADDRESS_201698]’s 
informed consent to participate in the screening phase as well as the intensive monitoring phase (if qualifying viremia is subsequently identified). 
 
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
22 
 Consented subjects can be enrolled as early as 4 weeks and as late as 100 days following 
renal/renal-pancreas transplant surgery. The 4-week delay prior to enrollment and initiation of 
specimen collection will allow post-transplantation stabilization of renal function, 
immunosuppressive dosing, and other clinical parameters.   
 
4.2.  Prospective Screening Phase 
Approximately 450 subjects will be screened for BK vi remia (15% over-enrollment allowed, to a 
maximum of 518 screened subjects).  During the screening phase, subjects will submit blood 
(plasma) for quantitative measurement of BKV DNA approximately every 4 weeks, ± 7 days, for 6 
months (timed from the date of transplantation) and then approximately every 8 weeks, ± [ADDRESS_201699] availability. If qualifying BK viremia is not 
detected, surveillance will terminate approximately 12 months after the date of transplantation (or 
when another study termination endpoint is reached, whichever occurs sooner). 
 
NOTE: BKV PCR results of >10,000 from the study central laboratory, the site laboratory, or a 
reference laboratory are acceptable to qualify the patient for inclusion in the Intensive Monitoring Phase of the study.   
 
NOTE: Non-study patients who are determined to have a qualifying blood BK viral load (>10,000 
copi[INVESTIGATOR_014]/ml) during the course of routine clinical care (i.e., patients not consented and not identified 
by [CONTACT_171897]/surveillance) will also be e ligible for enrollment directly into the intensive 
monitoring surveillance phase after providing consent as long as they remain within the window of 
< 100 days following transplantation. 
 
Subjects will remain in the screening/surveillance phase: 1) for [ADDRESS_201700]-transplantation; 2) 
until qualifying BK viremia is documented; 3) until renal graft failure, re-transplantation, and/or 
initiation of chronic dialysis occurs; 4) death; 5) until subject decides to terminate participation; 6) until the investigator decides that the subject should terminate participation; or 7) until the study 
closes (whichever occurs first). Reason for te rmination of participation in the study will be 
documented.  
 
4.3.  Intensive Sampling Phase 
Approximately 40 viremic subjects (up to a maximum of 60) will be asked to participate in 
more intensive sampling. Those subjects in whom BK viremia is identified (by [CONTACT_171898] >10,000 copi[INVESTIGATOR_014]/ml) will be shifted to a more intensive sampling 
schedule.  A review of the informed consent will be initiated by [CONTACT_171899]’s conti nued willingness and ability to par ticipate in the intensive 
monitoring phase until resolution of  viremia or until another di scontinuation event occurs.  
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
23 
 Blood and urine specimen collection will occu r every 2 weeks, ± 7 days, until the BK 
viremia has resolved (or another study termination endpoint is reached).  Resolution of BK viremia 
is defined as PCR becoming negative (or viral load <1000 copi[INVESTIGATOR_014]/ml).  Start and stop dates for the 
Intensive Sampling Phase will be defined by [CONTACT_171900] (initial positive and 
subsequent negative) blood samples were drawn.   
 
4.4.  Post-Viremia Follow-Up 
Following resolution of viremia, subjects will return to the previous sampling schedule 
(approximately every 4 weeks, ± 14 days) fo r an additional 6 months (or until another study 
termination endpoint is reached, whichever occurs sooner). The first follow-up visit should occur approximately [ADDRESS_201701]-viremia follow-up phase: 1). for 6 months following resolution of the 
BK viremia; 2). until another study termination endpoint is reached; 3). until death; 4). until they decided to terminate participation; 5). until the investigator decides that the subject should 
terminate participation; or 6). until the study closes  (whichever occurs first). Reason for termination 
of study participation will be documented. 
 
4.5.  Specimens for Biomarker Studies 
Detection of tubular injury by [CONTACT_171901][INVESTIGATOR_171873].  Coupled with urine PCR, 
detection of renal tubular injury in recipi[INVESTIGATOR_171874] a simple technique.  Urine markers of injury 
have already been identified in other causes of acut e kidney injury and are commercially available.  
These include cystatin C, renin, clusterin, Kim-1, b2-microglobulin, osteopontin, retinol binding 
protein, and markers of cell apoptosis.  For biom arker studies, approximately 100 mL of urine will 
be collected, aliquoted and stored at -70C on each subjects at each scheduled study visit (see 
MOP for details).  Urine will also be collected at the time of any renal biopsy, if performed.  We will 
retrospectively analyze expression of these urine ma rkers of injury using urine specimens collected 
at the time of detection of BK virus (in urine and/or blood) and at serial time-points. Using 
appropriate control specimens, values will be compared for: 1) Subjects who are BK viremic vs. 
non-viremic; 2) Subjects who subsequently dev elop BKVN vs. subjects with stable GFR vs. 
subjects with declining GFR attributed to a cause other than BKVN. 
 
4.6.  Documenting Special Events 
Specific clinical events and outcomes that may be related to BKV infection will be recorded, including: 
 subject death 
 loss of graft function as defined by [CONTACT_171895] <10 mL/min/1.73 m
2 
 development of urinary outlet obstruction 
 development of gross hematuria 
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
24 
  development of lymphocele  
 acute rejection 
 initiation of dialysis 
 re-transplantation 
 renal biopsies – Should renal biopsy be performed per standard-of-care during the 
course of the study, results will be submi tted using information from the pathology 
report. 
 
All data will be recorded on source documents, then entered on eCRFs and submitted 
electronically.   
4.7.  Adverse Events 
No protocol-defined interventions are included in this study; thus, adverse event recording will not be required unless the event is related to a study-mandated procedure (e.g., phlebotomy). 
 
4.8.  Clinical Laboratory Data 
Specimens for laboratory studies will be collected as detailed in Section 7.2. 
 
4.9.  Study Visits  
The study visits for the screening phase will be ev ery 4 weeks ± 7 days for 6 months (timed from 
date of transplantation) and then every 8 weeks ±14 days. The study visits during the intensive 
monitoring period are every 2 weeks ± 7days until resolution of BK viremia and then every 4 weeks 
± [ADDRESS_201702] 
availability.   
 
Events occurring at each study visit are listed in Appendix A.  
  
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
25 
 5.  STUDY POPULATION 
 
5.1.  Study Population Selection 
 
All adult renal or renal-pancreas transplant patients who meet protocol inclusion/exclusion criteria are eligible for participation in this study.    
In an effort to capture subjects early in the course of the evolving BK infection and avoid subjects 
who have already developed evidence of BKVN, this protocol will emphasize consent in the early 
peri-transplant period.  Patients may be consented while hospi[INVESTIGATOR_171875]-transplantation (as early 
as 7 days prior to transplantation) or at an outpatient follow-up visit (as late as [ADDRESS_201703]-
transplantation).  The study enrollment visit and initial collection of protocol-defined specimens will take place between 4 weeks and 100 days followi ng renal or renal/pancreas transplantation. 
 
5.2.  Inclusion of Women, Children and Minorities  
 All adult renal or renal/pancreas transplant patients meeting protocol inclusion/exclusion criteria 
will be potentially eligible for participation in this study.  Subjects will not be excluded on the basis of gender or ethnicity. Since there is no known gender or ethnic predilection for BKV infection, it is 
expected that the percentage of women and minorities included in the study will reflect the local demographics of the renal or renal-pancreas transplant population at the participating sites.  
 5.3.  Inclusion/Exclusion Criteria  
 
5.3.1.  Inclusion Criteria 
 
 Renal or renal-pancreas transplant patients who are within the informed consent window (as 
early as [ADDRESS_201704]-transplantation).   
 Age > 18 years; 
 Willing and able to understand and provide written informed consent. 
 
5.3.2.  Exclusion Criteria 
  Evidence of proven or suspected BKVN by c linical or pathologic diagnostic criteria; 
 Initiation of chronic dialysis post-transplantation due to graft failure. 
 
 
 
  
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
26 
 6.0.  SCHEDULE  OF EVENTS 
 
6.1.  Enrollment Visit  (Day 1) 
 Subjects who meet criteria for the eligibility criteria and have provided informed consent should be 
scheduled for an Enrollment Visit. The enrollment visit should be scheduled no sooner than 4 weeks after the transplant, but not more than 100 days after the transplant.  At the initial 
Enrollment Visit, the following assessments should be performed: 
 
1. Confirm that informed consent has been obtained and that the subject still wishes to 
participate;   
2. Review the inclusion-exclusion criteria to assure that the patient remains eligible for 
study participation. Subjects who are not willing or eligible to participate in the clinical trial should be logged as screen failures and reported on the Failed Screening page 
located on the Central Unit website. 
3. Record donor and recipi[INVESTIGATOR_171876], to include: 
a. Donor-derived factors:  
i. Deceased donor – Standard criteria donor (SCD), Donor after cardiac 
death (DCD), Expanded criteria donor (ECD) 
ii. Living donor – related donor or unrelated donor 
iii. ABO incompatibility  
iv. Total HLA mismatches 
v. HLA C7 status  
vi. Age 
vii. Race/ethnicity 
viii. Sex 
b. Recipi[INVESTIGATOR_841]-derived factors:  
i. Delayed graft function (DGF), defined as use of dialysis within 7 days of 
the transplant  
ii. Cold ischemia time (CIT) 
iii. Warm ischemia time (WIT)  
iv. Use of stents  
v. HLA C7 status 
vi. Type/intensity of immunosuppression, including corticosteroids 
vii. Acute rejection  
viii. Age 
ix. Race/ethnicity  
x. Sex 
 
4. Document  medical and surgical history  
5. Document use of selected concomitant medications (specifically, antiviral agents, 
immunomodulators, and immunosuppressive m edications – see the listing provided in 
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
27 
 the MOP).  Record all immunosuppressive drugs administered since transplantation, 
including peri-operative induction therapy with biological agents; 
6. Document blood concentrations of immunosuppressive drugs measured for clinical 
reasons; 
7. Obtain blood for serum creatinine determination and estimated GFR (if these studies 
were performed for routine standard-of-care within 7 days prior to enrollment, then the results of those assays can be recorded for study purposes); 
8. Collect 10 ml of blood for study-specified PCR assays (BK and other viruses), to be 
performed at the UAB Central Laboratory. Blood will collected, separated to plasma, then stored and shipped per instructions in the Manual of Procedures; 
9. If blood BK PCR was performed for routine standard-of-care in a local or reference 
laboratory, record the results of that assay as well. (Specimen for PCR will still be submitted to the UAB Central Laboratory); 
10.  Optional urinalysis - if UA was performed for routine standard-of-care with 7 days of 
enrollment, then the results of those assays can be recorded; 
11. Obtain a urine sample (approximately 100 ml) for study-specified PCR assays (BK and 
other viruses) and measurements of urinary biomarkers to be performed at the UAB Central Laboratory.  Urine will be collected, stored, and shipped per instructions in the 
Manual of Procedures. 
12. Notify the UAB Central Unit if the subject has consented to any other research study. 
 
6.2.  Screening Study Visits (approximately every 4 weeks +/- 7 days for 6 months and then 
approximately every 8 weeks +/- 14 days for 6 months)  
 
At each subsequent protocol-defined screening visit, the following events will occur:  
1. Document interval medical history to specifically include: 
a. subject death, b. loss of graft function as defined by [CONTACT_171895] <10 mL/min/1.73 m
2 
c. development of urinary outlet obstruction d. development of gross hematuria e. development of lymphocele  
f. acute rejection 
g. initiation of dialysis h. re-transplantation 
i. renal biopsies – Should renal biopsy be performed per standard-of-care during the 
course of the study, record the results from the pathology report. 
 
2. Document use of selected concomitant medications (specifically, antiviral agents, 
immunomodulators, and immunosuppressive medications – see MOP for listing); 
3. Record blood concentrations of immunosuppressive drugs obtained for clinical care 
purposes; 
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
28 
 4. Obtain blood for serum creatinine determination and estimated GFR (if these studies were 
performed for routine standard-of-care within 7 days prior to the study visit, then the 
results of those assays can be recorded for study purposes); 
5. Obtain 10 ml of blood for study-specified PCR assays (BK and other viruses), to be 
performed at the UAB Central Laboratory. Blood will collected, separated to plasma, then stored and shipped per instructions in the Manual of Procedures;  
If blood BK PCR was performed for routine standard-of-care at a local or reference laboratory, record the results of that assay in the research record; 
6. Optional urinalysis - if UA was performed for routine standard-of-care within 7 days of 
enrollment, then the results of those assays can be recorded); 
7. Obtain urine (approximately 100 ml) for subsequent study-specified PCR assays (BK and 
other viruses) and measurements of urinary biomarkers to be performed at the UAB Central Laboratory. Urine will be collected, stored, and shipped per instructions in the Manual of Procedures. 
8. Notify the UAB Central Unit if the subject has consented to any other research study. 
 
 6.3.  Intensive Monitoring Phase for BK Viremic Subjects:  (approximately every 2 weeks +/- 
7 days until viremia has resolved (PCR negative or <1000 copi[INVESTIGATOR_014]/ml), then approximately 
every 4 weeks +/-14 days for 6 months). 
 
At each protocol-defined study visit, the following events will occur:  1.  Document interval medical history to specifically include: 
a. subject death, b. loss of graft function as defined by [CONTACT_171895] <10 mL/min/1.73 m
2 
c. development of urinary outlet obstruction 
d. development of gross hematuria 
e. development of lymphocele  f. acute rejection 
g. initiation of dialysis 
h. re-transplantation i. renal biopsies – Should renal biopsy be performed per standard-of-care during the 
course of the study, record the results from the pathology report.  
2. Document use of selected concomitant medications (specifically, antiviral agents, 
immunomodulators, and immunosuppressive medications – see MOP for listing); 
3. Record  blood concentrations of immunosuppressive drugs obtained for clinical care purposes; 4. Obtain blood for determination of creatinine and GFR.  If results of serum creatinine and GFR 
obtained for clinical care purposes (within 7 days) are available, those results may be used instead; 
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
29 
 5. Obtain 10 ml of blood for study-specified PCR assays (BK and other viruses), to be performed 
at the UAB Central Laboratory.  Blood will collected, separated to plasma, then stored and 
shipped per instructions in the Manual of Procedures;  
6. If blood BK PCR was performed for routine standard-of-care at a local or reference laboratory, 
record the results of that assay in the research record; 
7. Optional urinalysis – if results of urinalysis obtained for clinical care purposes (within 7 days) 
are available, those results may be recorded; 
8. Obtain urine (approximately 100 ml) for subsequent study-specified PCR assays (BK and other 
viruses) and measurements of urinary biomarkers to be performed at the UAB Central 
Laboratory. Urine will be collected, stored, and shipped per instructions in the Manual of Procedures. 
9. Notify the UAB Central Unit if the subject has consented to any other research study. 
 
6.4.  Subject Early Termination  
 
Subjects will be terminated from the study for any of the following reasons: 
 Death;  
 Initiation of chronic dialysis for loss of graft function; 
 Re-transplantation; 
 Inability or unwillingness to comply with study requirements. 
 
6.5.  Management of Subject Withdrawals 
 
Study subjects may withdraw voluntarily from part icipation in the study at any time.  If a study 
subject withdraws or is discontinued from the study at any time prior to completion of the study, the reason for this decision will be recorded on the study termination page of the eCRF. 
 
6.6.  Termination of Study 
 
The UAB Central Unit (in consultation with DMID) and NIH/NIAID have the right to terminate this study at any time.  Reasons for terminating the study may include, but are not limited to, the 
following: 
 
 Study subject enrollment is unsatisfactory; 
 Data recording is inaccurate or incomplete; 
 Investigators do not adhere to the protocol or applicable regulatory guidelines in conducting the 
study. 
  
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
30 
 7.0.  STUDY PROCEDURES  
 The scheduled study procedures and evaluations are summarized in Appendix A.   
 
7.1.  Demographics, Baseline Medical-Surgical History, Clinical Outcomes  
At the time of enrollment, baseline demographics and medical-surgical history (cardiovascular, 
respi[INVESTIGATOR_696], musculoskeletal, gastrointestinal, lymphatic, urinary, nervous, endocrine, skin, reproductive, EENT)  will be obtained from the medical charts or from subject interviews.  Transplant-specific history (HLA match, organ source, surgical date and select donor and recipi[INVESTIGATOR_171877]) will be recorded. 
 
 
At subsequent visits, changes in the medical and surgical history will be documented (including selected concomitant medications, immunosuppre ssive drug levels and pathology results from 
renal biopsies conducted for clinical care).  Clinical outcomes will be recorded including subject 
death, loss of graft function, acute graft rejection or initiation of dialysis.
 
 
7.2.  Laboratory – Specimen Collection 
 7.2.1.  At Each Screening Visit: 
 
Blood: 
 Blood (10 ml) for viral PCR submitted as plasma to UAB Central Laboratory).   
 Serum creatinine and GFR performed at local laboratory (or results of assay performed for 
clinical standard-of-care will be recorded) 
 
Urine: 
 specimen  (approximately 100 ml) for biomarkers and viral PCR (UAB Central laboratory)  
 optional urinalysis (dipstick and microscopic, to include: pH, bilirubin, blood, nitrite, protein, 
specific gravity, glucose, ketones, RBC/HPF, WBC/HPF, urobilinogen, leukocyte esterase) 
performed at local laboratory (or results of assay performed for clinical standard-of-care can  
be recorded)   
 
7.2.2.  At Each Intensive Follow-up Visit for Viremic Subjects: 
 Blood: 
 Blood (10 ml) for viral PCR submitted as plasma to UAB Central Laboratory.   
 Serum creatinine and estimated GFR – performed at local laboratory (or results of assay 
performed for clinical standard-of-care will be recorded)  
 
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
31 
  
Urine: 
 Optional urinalysis (dipstick and microscopic, to include: pH, bilirubin, blood, nitrite, protein, 
specific gravity, glucose, ketones, RBC/HPF, WBC/HPF, urobilinogen, leukocyte esterase) 
performed at local laboratory (or results of assay performed for clinical standard-of-care can be 
recorded)   
 specimen  (approximately 100 ml) for biomarkers and viral PCR (UAB Central laboratory)  
 
7.3.  Reporting of Concomitant Medications 
 
Only selected concomitant medications will be recorded at each subject visit. Only the following will 
be reported:    immunosuppressive drugs (including peri-transplant induction therapy), 
 immunomodulators,  
 antiviral drugs. 
 
 A list of the selected medications is found in the Manual of Procedures. The generic name [CONTACT_171913], the dosage, the route, and the start/stop dates of administration will be recorded in the appropriate sections of the eCRF. Failure to document use of selected concomitant medications 
will be considered a protocol deviation. 
 
7.4.  Dosing of Immunosuppressive Drugs  
 
Immunosuppressive (IS) drug selection and doses will be determined by [CONTACT_171902]/investigator in accordance with best c linical practice and local treatment standards.  
Modification of immunosuppressive drug dosing in response to documented BK viremia (or other 
indications) may be performed at the discretion of  the treating physicians/investigator. All doses 
and dose changes should be documented in the conc omitant immunosuppressive medications 
section of the eCRF. Failure to document concomitant medication information will be reported as a protocol deviation during screening/surveillance and intensive monitoring periods. 
 
Measurements of immunosuppressive drug levels ar e not a protocol requirement.  However, IS 
levels that are obtained for standard-of-care medical management during the study will be 
recorded on the eCRF.  
 
7.5.  Measurement of Viral DNA  
 
BKV DNA levels will be measured at the UAB Central Lab.  Plasma specimens will be shipped to the UAB Central Laboratory once weekly (Monday through Thursday – see Manual of Procedures 
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
32 
 for details) for real-time viral load determinations. The BKV DNA in plasma will be assayed using a 
quantitative PCR assay. Assays will be perform ed approximately once weekly and results will be 
shared with the site investigators as soon as they are available.  
 NOTE: BK PCR assays performed on specimens co llected during the post-viremia follow-up period 
will not be run in real time; real-time results will not be available to the investigator.  These can be batch-shipped at the conclusion of the follow-up period. 
Retrospective analysis of urine for BKV DNA and tubular injury biomarkers will be performed in 
viremic subjects where correlations between viremia and viruria can be made.  PCR of urine for BKV DNA will not be  performed in real time.  Urine specimens for PCR and for biomarker assays 
will be collected, frozen, and batch-shipped to the UAB Central Laboratory (see Manual of 
Procedures for details). 
Plasma and urine assays for other non-BK viral pathogens will be performed retrospectively.  
These assays will not be  performed in real time and results will not be  provided to the site 
principal investigators in real time.  
Any blood BKV DNA result obtained at the local (or reference) laboratory for standard-of-care 
purposes will be reported on the eCRF.  
7.6.  Specimen Preparation, Handling and Shippi[INVESTIGATOR_171878], shippi[INVESTIGATOR_171879].  
 
  
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
33 
 8.  STATISTICAL CONSIDERATIONS 
 
8.1.  Study Hypothesis 
 
Elucidation of the natural history of BK viremia in renal transplant patients will identify those groups at high risk for developi[INVESTIGATOR_171880] (when 
these become available). In particular, it is of interest to compare the change in the glomerular filtration rate (GFR) a year after transplant between the BKV viremic and non-viremic subjects. We hypothesize that BKV viremia will have a negative effect on renal function as measured by [CONTACT_171895].   
8.2.  Sample Size Considerations 
 
8.2.1.  Sample Size 
 
We propose to enroll approximately 450 (up to a maximum of 518) patients in this study. The 
sample size justification is based on observing a target number of BKV viremia patients from the 
patients enrolled in the screening group. Table 1 below shows varying values of proportion of patients with BKV viremia. Figure 1 summarizes the probability of observing K number of BKV 
patients (K=30, 35, 40, 45, and 50) assuming varying values of true proportion of BKV viremia 
patients (3% to 17%) out of 450 enrolled patients. To interpret this graph, assume that the true proportion of BKV viremia patients is 10%. Then the probabilities of observing at least 30, 35, 40, 
45, and 50 BKV viremia patients out of the 450 enrolled are about 0.99, 0.94, 0.76, 0.46, and 0.19, 
respectively.  
In this study, we would like to target approximately 40 BKV viremia patients (up to a maximum of 
60). From Figure 1, enrolling [ADDRESS_201705] 90% probability of identifying at least [ADDRESS_201706] 11%. 
 
Table 1 
Location Study Type Sample size 
(N) % with BKV viremia Reference 
[LOCATION_003]3 Prospective 200 11.5% Brennan 2005 
Spain5 Prospective 156 12.2% Munoz 2005 
[LOCATION_003]23 Prospective   66 16.6% Petrov 2009 
Czech Republic24 Prospective 120      6% Girmanova 2011 
[LOCATION_003]25 Retrospective 134    16% Koleilat 2011 
  
  
  
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
34 
 Figure 1: Probability of Observing a Given Number of BKV Subjects or More as a function of True 
Percent with BKV  viremia  
 
 
We are also interested in comparing the change in GFR between those with and without BKV 
viremia. In this power analysis, we will only be concerned about the change from baseline (time of 
enrollment) to Month 12 (time post-transplant). Assuming the standard deviation of the change in GFR is assumed to be the same for those with and without BKV viremia and equals 10.9 
ml/min/1.73 m2 (Ref: Srinivas TR, Flechner SM, Poggi o ED, et al. Glomerular filtration rate slopes 
have significantly improved among renal transplants in the [LOCATION_002]. Transplantation 2010; 
90:1499-505.). With [ADDRESS_201707] 5.9 ml/min/1.73 m2 with 90% power between these two groups of subjects at 5% level of significance based on a t-test. In the final analysis, we will be using all available GFR data for each subject which should increase the power as more 
information is used. This will enable us to still use data from subjects who dropped out before the 
end of the study.
 
 
 8.2.2.  Estimated Annual Accrual 
 
We anticipate enrolling approximately [ADDRESS_201708] 
deviations for continuous variables and counts and proportions for categorical variables. ANOVA 

                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
35 
 (or its nonparametric analog Krusall-Wallis) for continuous variables and Fisher’s exact test for 
categorical variables will be utilized to compare these characteristics.  Demographic characteristics 
will be summarized in tabular format.  
 
8.4.  Final Analysis Plan 
 
All statistical tests will be performed at 5% significance level and confidence interval at 95% level. 
There will be no adjustment on the levels for multiple testing. There will also be no imputation 
methods that will be used for missing data. Any viral load <100 (i.e., undetectable) will be replaced 
by [CONTACT_171903] 10. Quantitative viral loads will be analyzed based on the log based 10 transformation.  
 
  8.4.1.  Primary Outcome Analysis 
 
Incidence of BK viremia will be estimated using a 95% confidence interval for single proportion. 
Logistic regression will be used to investigate the risk factors for BKV viremia and BKVN. Factors 
will include: 
o Donor-derived factors:  
1. Deceased donor – Standard criteria donor (SCD), Donor after cardiac death 
(DCD), Expanded criteria donor (ECD) 
2. Living donor – related donor or unrelated donor 
3. ABO incompatibility  
4. Total HLA mismatches 5. HLA C7 status  
6. Race/ethnicity 
7. Sex 
o Recipi[INVESTIGATOR_841]-derived factors:  
1. Delayed graft function (DGF), defined as use of dialysis within 7 days of the 
transplant  
2. Cold ischemia time (CIT) 3. Warm ischemia time (WIT)  
4. Use of stents  
5. HLA C7 status 6. Type/intensity of immunosuppression, including corticosteroids 
7. Acute rejection  
8. Age 9. Race/ethnicity  
10. Sex 
To compare the change in GFR over time between those with and without BKV viremia, we use all 
available GFR data from each subject.  We will use mixed model for repeated measures to analyze 
the GFR data over time. This analysis method will allow us to use any of the available GFR data 
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
36 
 even if they are not complete. We will determine the appropriate covariance structure to use as 
indicated by [CONTACT_171904].  
 
8.4.2.  Secondary Endpoints 
  
The distribution of the time to onset and duration of BKV viremia will be estimated using survival 
analysis methods such as Kaplan-Meier estimator for a single group. This will provide estimates of 
the median time to onset or median duration of BKV viremia. To compare different groups and/or determine risk factors, we will use Cox proportional hazard regression model if the proportional 
hazards assumption is found to be reasonable. Otherwise, we will consider using parametric 
survival regression models (in particular, accelerated failure time model). Parametric regression models are useful especially in cases where samp le sizes are small or when the percent censored 
is high. This will also be the tool of preference if there will be left-censored subjects, i.e., subjects who at enrollment show evidence of BK viremia. Cox model cannot handle left-censored data. 
 
As with the BKV viremia, incidence of BKVN will be estimated using a 95% confidence interval for 
single proportion.  We will utilize logistic regres sion to compare groups, or adjust for covariates or 
determine risk factor. 
 
To investigate the change in the quantitative BK viremia over time and how it is associated with 
important factors such as the use of immunosuppressive therapy and recipi[INVESTIGATOR_841]’s demographic and clinical characteristics, we will again use mixed regression modeling for repeated measures.  
 
8.4.3.  Exploratory Endpoints 
 
To investigate the association between the incidence between BK viremia and BK viruria, we will 
utilize the Fisher’s exact test or the large-sample chi-squared test for association whichever is 
applicable. Time to onset and duration of BK viremia and BK viruria will be analyzed using survival analyses. 
 
Logistic regression will be utilized to determine if other viruses such as CMV, adenovirus, etc. are risk factors for BK viremia. This tool will also be used to determine if selected urinary biomarkers of tubular injury are predictors of BKVN. 
 
To assess the relationship of the time to developm ent of BKVN with the use of immunosuppressive 
therapy, we will use survival regression analysis with the length of use of immunosuppressive 
weighted by [CONTACT_171905] a predictor variable of interest. 
 
Finally, to examine the reproducibility of the quantitative PCR assays at the participating sites and 
PCR assays at UAB, we compute the differences in the results and construct a 95% confidence 
interval for the mean difference. We will also create a Bland-Altman plot which will display the 
differences and their 95% confidence intervals as a function of the mean readings of the two PCR results.
  
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
37 
 9.  SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/ 
DOCUMENTS 
 
Documentation of source data is necessary for the reconstruction, evaluation, and validation of 
clinical findings, observations, and other activities  during a clinical trial.  Source documentation 
serves to substantiate the integrity of trial data, confirms observations that are recorded, and 
confirm the existence of study participants.  Thi s standard also serves to ensure data quality by 
[CONTACT_114806], complete, and accurate.  DMID 
studies will be monitored using these standards. 
 
Sites that are participating in this trial should consult the MOP, Central Unit website, and DMID/NIAID Source Document Standards (most current version) for specific instructions and 
forms. 
 Local, state, institution, IRB/independent ethics committee (IEC) policies and procedures may be different from those stated in this standard.  The site should refer to local, state, institution, IRB/IEC 
policies and procedures and follow them if they are more stringent than the DMID Standards. 
 
According to the ICH E6 Guidelines 4.9, “The investigator should ensure the accuracy, 
completeness, legibility, and timeliness of t he data reported to the sponsor in the CRFs 
and in all required reports.  Data reported on the CRFs, which are derived from source 
documents, should be consistent with the s ource documents or discrepancies should be 
explained.” 
 
  
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
38 
 10.  QUALITY CONTROL AND QUALITY ASSURANCE  
 
The study site will implement a quality management plan. The quality management procedures are described herein, as well as in the Manual of Procedures and the study site quality management 
plan (QMP). Per the QMP, data will be evaluated for compliance with the protocol and accuracy in 
relation to source documents. The study will be conducted in accordance with procedures identified in the protocol. Items to be reviewed include, but are not limited to: eligibility (including 
informed consent), any required AE reporting, study/clinical endpoints, follow-up visits, regulatory 
documents, missed calls, and review of clinical records. Data that will be reviewed, who is responsible for implementation, and the schedule for internal reviews will be specified or 
referenced in the quality management plan.  
 The UAB Statistical and Data Coordinating Cent er will implement quality control procedures 
beginning with the data entry system, and will generate data quality control checks that will be run 
on the database within [ADDRESS_201709] 
 This trial will be conducted in compliance with the protocol, International Conference on 
Harmonization E6 Good Clinical Practice (ICH E6 GCP), and the applicable regulatory requirements, including: 
 
 U.S. Code of Federal Regulations applicable to clinical studies (45 CFR 46 and 21 CFR 11 
including parts 50 and 56 concerning informed consent and IRB regulations). 
 Completion of Human Subjects Protection Training.  Refer to 
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-01-061.html ; 
http://cme.cancer.gov/clinicaltrials/learning/humanparticipant-protections.asp   
 
11.2.  Institutional Review Board 
 Reviewing IRBs must be registered with the OHRP to conduct FDA-regulated studies.  In the United 
States and in other countries, only institutions holding a current US Federalwide Assurance (FWA) issued by [CONTACT_171906]. 
 
This protocol, informed consent documents, relevant supporting information, and all types of volunteer recruitment or advertisement information will be submitted to the Institutional Review 
Board (IRB) for review and must be approved before the study is initiated.  Any amendments to the 
protocol must also be approved by [CONTACT_114811].   
The investigator is responsible for keepi[INVESTIGATOR_171881], but in any case at least once per year.  The investigator must also keep the IRB informed of any significant AEs. 
 
All IRB approved documents as well as relev ant study correspondence should be copi[INVESTIGATOR_171882]. 
 
11.3.  Informed Consent Process 
 
The process of obtaining informed consent must be documented in the medical records, clinic 
chart, and/or research chart.  The consent form must be signed and dated by [CONTACT_114812]/study participant’s legal guardian before par ticipation in the study.  Only in the case of 
an established legal guardian may the consent be signed by [CONTACT_171907].  A 
copy of the signed consent form must be provided to the study participant/study participant’s legal 
guardian.  Signed consent forms must remain in each study participants study file and must be available for verification by [CONTACT_9534].  
 
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
40 
 The investigational nature and research objectives of this trial, the procedure, and its attendant 
risks and discomforts will be carefully explained to the study participant/study participant’s legal 
guardian.  A signed informed consent document will be obtained from each study participant/study participant’s legal guardian prior to entry into this study.  At any time during participation in the protocol, if new information becomes available relati ng to risks, AEs, or toxicities, this information 
will be provided orally or in writing to all enroll ed or prospective study participant/study participants’ 
legal guardian. Documentation will be provided to the IRB and, if necessary, the informed consent will be amended to reflect any relevant information. 
 
An investigator shall seek such consent only under circumstances that provide the prospective subject or the representative sufficient opportunity to consider whether or not to participate and 
that minimize the possibility of coercion or undue influence. The information that is given to the 
subject or the representative shall be in language understandable to the subject or the representative.  
Subjects/subject’s legal guardian will sign the informed consent document prior to any procedures 
being done specifically for the study.  Subj ects/subject’s legal guardian should have the 
opportunity to discuss the study with their family , friends or personal physician, or think about it 
prior to agreeing to participate.  Subjects/subje ct’s legal guardian may withdraw consent at any 
time throughout the course of the trial.  A copy of the informed consent document will be given to the subjects /subject’s legal guardian for their records.  The rights and welfare of the subjects will 
be protected by [CONTACT_171908]. 
 
If an investigator anticipates enrolling non-English subjects, he/she must provide an approved non-
English consent form.  The non-English consent form must be submitted to the Central Unit with an accompanying signed attestation that the non-English consent matches in content and meaning 
the IRB approved English consent.  If a subject presents him/herself for enrollment, the PI [INVESTIGATOR_171883], discussion and communicate other information to the study subject.   Assurance must  also be documented that the person proficient in 
the non-English language is available at all subject visits and at any time interaction is needed with the subject.  The Principle Investigator or designee will document the process.  
If a subject is unable to read or if a legally acceptable representative is unable to read, an impartial 
witness should be present during the entire informed consent discussion. After the written informed consent form and any other written information to be provided to subjects, is read and explained to the subject or the subject’s legally acceptable representative, and after the subject or the subject’s 
legally acceptable representative has orally consented to the subject’s participation in the trial and, 
if capable of doing so, has signed and personally dated the informed consent form, the witness 
should sign and personally date the consent form. By [CONTACT_17317], the witness attests 
that the information in the consent form and any other written information was accurately explained 
to, and apparently understood by, the subject or the subject's legally acceptable representative, 
                 
                            DMID Protocol 11-0071, Version 2.[ADDRESS_201710]’s legally acceptable 
representative.  The Principle Investigator and or designee will document the consenting process.  
 
11.4.  Exclusion of Women, Minorities, and Children (Special Populations) 
 All adult renal or renal-pancreas transplant patients with BKV viremia meeting protocol 
inclusion/exclusion criteria will be potentially eligible  for participation in this study.  Subjects will not 
be excluded on the basis of gender or ethnicity. Since there is no known gender or ethnic 
predilection for BKV infection, it is expected that the percentage of women and minorities included 
in the study will reflect the local demographics of the renal or renal-pancreas transplant population at the participating sites. Children will not be enrolled. 
 
11.[ADDRESS_201711] parties other than those noted below is prohibited.  The results of the research study may be 
published, but study participant’s names or identities will not be revealed.  Records will remain confidential.  To maintain confidentiality, the principal investigators at each site will keep records in 
locked cabinets and the results of tests will be coded to prevent association with volunteers’ 
names.  Data entered into computerized files will be accessible only by [CONTACT_114814].  However, subject specific information will be 
available to the clinical monitors, to the FDA and to health authorities where provided by [CONTACT_2371].    The study investigator is obliged to provide the NIAID/DMID and UAB Central Unit with complete 
test results and all data developed in this study.  The NIAID/DMID or UAB Central Unit may 
disclose this information to appropriate regulatory authorities as deemed necessary by [CONTACT_122845]/DMID or UAB Central Unit   
  
Subject-specific information may be provided to other appropriate medical personnel only with the study participant’s parent/legal guardian permission.  To ensure compliance with current ICH E6 
Guidelines, data generated by [CONTACT_25757], the NIAID/DMID, UAB Central Unit, and the IRB/IEC for each study site. 
 
11.6.  Recruitment and Compensation 
 Study participants will be recruited using IRB- approved approaches.  The investigators will make 
every effort to recruit adult male and female volunteers from all ethnic backgrounds. 
 
Consented study participants/legal guardians may rece ive nominal payments to offset the cost of 
travel, parking, and meals for study visits in accordance with local site policies and local IRB 
policies, procedures, and approval. 
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
42 
 11.7  Future Use of Stored Specimens  Some of the specimens obtained from study participants during this study (urine and plasma) will 
be stored indefinitely in the UAB Central Laboratory and may be used in future studies of viral infections in renal or renal-pancreas transplant patients.  These specimens will be labeled with a 
code number and not with the study participant’s name.  At the time of consent for st udy 
participation, study participants will have the opportunity to either agree or decline to have their 
specimens used in future research.  The study participant will indicate his/her preference by 
[CONTACT_171909], “Future Use of Specimens”.  Non-protocol designated, future testing of samples will be performed only on samples from study participants who have consented for future testing of 
samples.  These specimens will only be utilized to better understand the natural history of studies 
of viral infections in renal or renal-pancreas transplant patients or improve diagnosis.  A repository for residual samples will be establis hed according to OHRP guidelines ensuring that 
codes or other personally identifying links will not be distributed to future researchers.   The specimens will be stored indefinitely in the U AB Central Laboratory.  Specimens from study 
participants will be labeled and coded without study participant’s identifiers.  If the study participant has indicated in the signed consent form that he/she does not agree to allow the future use of specimens for future studies of viral infections in renal or renal-pancreas transplant patients, then 
his/her specimens will be destroyed at the completion of this study. 
 
 
  
                 
                            DMID Protocol 11-0071, Version 2.[ADDRESS_201712] KEEPI[INVESTIGATOR_171884], completeness, legibility, and timeliness of 
the data reported. 
Electronic case report forms (eCRFs) will be developed by [CONTACT_114818].  The eCRFs will be provided elec tronically by [CONTACT_114819].  Original 
data will be recorded on source documents (e.g., medical records, research progress notes, or 
Source Document Worksheets documenting research related procedures).  The DMID 11-[ADDRESS_201713]’s source documents.12.[ADDRESS_201714] be reviewed by [CONTACT_093]’s research team, under the supervision of the 
investigator, who will ensure that they are accurate and complete.  All data must be supported by 
[CONTACT_18412], which will remain available fo r review by [CONTACT_171910].  
Adverse events must be graded, assessed for intensity and causality, and reviewed by [CONTACT_171911]. 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the 
site PI.  During the study, the investigator must maintain complete and accurate documentation for 
the study. 
The UAB Central Unit and Statistical and Data Coordinating will be responsible for data management, quality review, analysis of the study data, and writing of the clinical study report.  
These tasks are detailed in the DMID 11-0070 DMP. 
 
12.1  Data Capture Methods 
 
Clinical and laboratory data will be entered into a 21 CRF Part 11 compliant electronic Data Entry 
System (eDES)  provided by [CONTACT_114823].  The data system 
includes password protection and internal quality checks, such as automated range checks, to identify data that appear to be inconsistent, incomplete, or inaccurate.   
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
44 
  
12.2  Types of Data 
 
Data for this study will include clinical laboratory and virologic results, and clinical and outcome 
measures. 
 
12.3  Timing/Reports 
 
There are no planned interim analyses or safety reviews for this trial.  There also are no stoppi[INVESTIGATOR_37626]. 
 
12.[ADDRESS_201715] be approved by [CONTACT_171912]/DMID prior to 
seeking approval from the IRB/IEC.  Each investigator will be responsible for enrolling only those 
study participants who have met pr otocol eligibility criteria. 
A protocol deviation is any noncompliance with t he clinical trial protocol, GCP, or Manual of 
Procedures requirements.  The noncompliance may be either on the part of the study participant, the investigator, or the study site staff.  As a result of deviations, corrective actions are to be developed by [CONTACT_3483].  
These practices are consistent with ICH E6 GCP sections: 
4.[ADDRESS_201716] be promptly reported to the UAB C entral Unit.  UAB will report all deviations to 
DMID in accordance with DMID’s instructions. 
All deviations from the protocol must be addressed in the source documents.  A completed copy of 
the DMID protocol deviation form must be maintained in the regulatory file (Project Notebook or 
designated location) as well as in the subject’s source documents.  A log of protocol deviation will 
be maintained in the Project Notebook.  Protocol deviations must be sent to the local IRB per the IRB’s guidelines.  The site PI/study staff is responsible for knowing and adhering to their IRB/IEC 
requirements. 
 
  
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
46 
 13.  PUBLICATION POLICY 
Following completion of this study, the investigators are expected to publish the results in a 
scientific journal.  All research reports and other publications resulting from the work completed in this protocol shall: 
 Acknowledge the support of the National Institutes of Health whenever publicizing the 
results from this clinical trial in any media. 
 Be submitted to the Project Director in the form of advance copi[INVESTIGATOR_171885]. 
 Be furnished in a list of publications resulting from the research as part of the annual 
progress report submitted to the principal investigator. 
The International Committee of Medical Journal Editors (ICMJE) member journals has adopted a 
trials-registration policy as a condition for publication.  This policy requires that all clinical trials be 
registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by [CONTACT_1055].  Other biomedical journals are considering adopting similar policies.  
 
Unless exempted, this trial will be registered prior to enrollment of study subjects.  It is the 
responsibility of the study’s PI (i.e., [CONTACT_171916]) to register the non-exempted trials and post results 
in compliance with Public Law 110-85, the Food and Drug Administration Amendments Act of 2007 
(FDAAA).  
 
  
 
  
 
  
 
   
 
 
 
                 
                            DMID Protocol 11-0071, Version 2.[ADDRESS_201717] Dis 2009; 199:837-46. 
2. Bohl DL, Brennan DC, Ryschkewitsch C, Gaudreault-Keener M, Major EO, Storch GA. BK 
virus antibody titers and intensity of infections after renal transplantation. J Clin Virol 2008; 
43:184-9. 
3. Geddes CC, Gunson, R, Mazonakis E, Wan R, Thomson L, Clancy M, Carman WF, BK 
viremia surveillance after kidney transplant: si ncle-center experience during a change from 
cyclosporine-based to lower-dose tacrolimus -based primary immunosuppresion regimen. 
Transpl Infect Dis 2011:13:109-[ADDRESS_201718]-Dec(5-6) 230-[ADDRESS_201719] of preemptive immunosuppression reduction. Am J Transplant 2005; 5:582-94. 
6. Helantera I, Egli A, Koskinen P, Lautenschlager I, Hirsch HH. Viral impact on long-term 
kidney graft function. Infect Dis Clin North Am 2010; 24:339-71. 
7. Munoz P, Fogeda M, Bouza E, Verde E, Palomo J, Banares R. Prevalence of BK virus 
replication among recipi[INVESTIGATOR_171886]. Clin Infect Dis 2005 ; 41:1720-5. 
8.   Gillispie M, Yost SE, Meister E, Kaplan B. A cautionary tale of BK virus:Letter to the 
Editors. Transpl Int 2013  e99. 
9.   Almeras C, Vetromile F, Garrigue V, Szwarc I, Foulongne V, Mourad G: Monthly screening 
for BK viremia is an effective strategy to prevent BK virus nephropathy in renal transplant 
recipi[INVESTIGATOR_840]. Transpl Inf Dis 2011: 13:101-108. 
[ADDRESS_201720] Inf  Dis 2009: 11: 1-10.  
11. Hirsch HH, Randhawa P. BK virus in solid organ transplant recipi[INVESTIGATOR_840]. Am J Transplant 
2009; [ADDRESS_201721] 4:S136-46. 
12. Bohl DL, Brennan DC. BK virus nephropathy and kidney transplantation. Clin J Am Soc 
Nephrol 2007; [ADDRESS_201722] 1:S36-46. 
13. Hirsch HH. BK virus: opportunity makes a pathogen. Clin Infect Dis 2005 ; 41:354-60. 
14. Nickeleit V, Mihatsch MJ. Polyomavirus nephr opathy in native kidneys and renal allografts: 
an update on an escalating threat. Transpl Int 2006 ; 19:960-73. 
15. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK 
replication and nephropathy in renal-transplant recipi[INVESTIGATOR_840]. N Engl J Med 2002; 347:488-96. 
16. Mannon RB, Hoffmann SC, Kampen RL, Cheng OC, Kleiner DE, Rvschkewitsch C, et al. 
Molecular evaluation of BK polymaviru nephropathy.  Am J Transplant 2005; 5(12):2883-
93. 
17. Josephson MA, Williams JW, Chandraker A, Randhawa PS. Polyomavirus-associated 
nephropathy: update on antiviral strategies. Transpl Infect Dis 2006; 8:95-101. 
18. Smith F, Panek R, Kiberd BA. Screening to prevent polyoma virus nephropathy in kidney 
transplantation: a cost analysis. Am J Transplant 2009; 9:2177-9. 
                 
                            DMID Protocol 11-0071, Version 2.0 BK Natural History                           22 March 2016 
 
 
48 
 19. Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in 
renal transplantation: interdisciplinary analyses and recommendations. Transplantation 
2005; 79:1277-86. 
20. Randhawa P, Brennan DC. BK virus infection in transplant recipi[INVESTIGATOR_840]: an overview and 
update. Am J Transplant 2006; 6:2000-5. 
21. Petrov R, Elbahloul O, Gallichio MH, Stellrecht K, Conti DJ. Monthly screening for polyoma 
virus eliminates BK nephropathy and preserves renal function. Surg Infect (Larchmt) 2009; 
10:85-90.  
22 Girmanova E, Brabcova I, Bandur S, Hribova P, Skibova J, Viklicky O. A prospective 
longitudinal study of BK virus infection in 120 Czech renal transplant recipi[INVESTIGATOR_840]. J Med Virol 2011; 83:1395-400.  
23. Koleilat I, Kushnir L, Gallichio M, Conti DJ. Initiation of a screening protocol for polyoma 
virus results in a decreased rate of opportunistic non-BK viral disease after renal transplantation. Transpl Infect Dis 2011; 13:1-8. 
 
 
                       DMID Protocol 11-0071, Version 2.0 
B K  N a t u r a l  H i s t o r y                2 2  M a r c h  2 0 1 6  
 
 
 
49 
 APPENDIX A-1:  Table of Study Procedures -  Screening  Phase  
 
Procedures 
A 4 weeks 
to 100 
days 
Baseline  
Month 1 
Month 2 
Month 3 Month 4 
Month 5 
Month 6 Month 8 
Month 10 
Month 12
 
1 Review informed consent 
 X          
Assess eligibility criteria-inclusion/exclusion  X          
1a Record medical/ surgical history X          
[ADDRESS_201723] IS drug trough levels X X X X X X X X X X 
4 Obtain >[ADDRESS_201724] selected concomitant  medications X X X X X X X X X X 
6 Serum Creatinine, estimated GFR  (local lab) X X X X X X X X X X 
7 Urinalysis - optional  (local lab) X X X X X X X X X X 
8Study Termination          X 
 LEGEND 
A   The post‐transplant  specimen  collection  and study procedures  should not be implemented  until 4 weeks (out to 100 days) post‐transplant  
1 The informed  consent may be obtained  during  the peri‐transplant  admission  (as early as T‐7 days) out to T+100  days1a  The medical history 
includes assessment  of the following:  cardiovascular,  respi[INVESTIGATOR_696],  musculoskeletal,  gastrointestinal,  lymphatic,  urinary, nervous, endocrine,  skin, 
reproductive  and EENT  Surgical  history includes organ source,  and date of surgery . 
[ADDRESS_201725]  donor/recipi[INVESTIGATOR_171887]: donor= [deceased,  living, ABO incompatibility,  total  HLA  mismatches,  HLA  C7, age, race/ethnicity,  sex] 
recipi[INVESTIGATOR_841]=  [delayed graft function(DGF),  cold  ischemia time (CIT), warm ischemia time (WIT), use of stents, HLA  C7 status, type/intensity  of 
immunosuppression,  acute rejection,  race/ethnicity,  age, sex] 
                       DMID Protocol 11-0071, Version 2.[ADDRESS_201726] death, loss of graft function as defined by [CONTACT_171895] <10 mL/min/1.73 m2, development of urinary outlet obs truction, development of gross 
hematuria, development of lymphocele  acute rejection, initiati on of dialysis, re-transplantati on, renal biopsies – Should rena l biopsy be performed 
per standard-of  
[ADDRESS_201727]  selected concomitant  medication  generic name  [CONTACT_171914], start/stop  date,  and route of administration,  failure  to record,  report as a 
protocol deviation.  
[ADDRESS_201728] of care. 
7 Optional ‐ Record  urinalysis  results performed  at local lab for dipstick and microscopic  for pH, bilirubin, blood, nitrate, protein, specific gravity, 
glucose, ketones, RBC/HPF,   WBC/HPF,  urobilinogen,  leukocyte  esterase 
[ADDRESS_201729]‐transplantation.  
  
                       DMID Protocol 11-0071, Version 2.0 
BK Natural History                            22 March 2016 
 
 
 
 
51 
 APPENDIX A-2:  Table of Study Procedures  for BK Viremia Intensive Sampling Phase 
 
LEGEND: 
A When diagnosed  with BK Viremia,  perform  procedures  every [ADDRESS_201730] death, loss of graft function as defined by [CONTACT_171895] <10 mL/min/1.73 m2, development of urinary outlet obstruction, development of gross 
hematuria, development of lymphocele  acute rejection, initiati on of dialysis, re-transplantati on, renal biopsies – Should rena l biopsy be performed 
per standard-of care. 
[ADDRESS_201731] of care Procedures BK Viremia 
diagnosis BK viremia   monitoring  
A Every 2 weeks +/- 
[ADDRESS_201732] IS trough levels   X X X X X X X 
4 Obtain >[ADDRESS_201733] selected concomitant  medications  X X X X X X X 
6 Serum Creatinine, estimated GFR  (local lab)  X X X X X X X 
7 Urinalysis - optional  (local lab)  X X X X X X X 
Study Termination        X 
                       DMID Protocol 11-0071, Version 2.[ADDRESS_201734]  selected concomitant  medication  generic name  [CONTACT_171914], start/stop  date,  and route of administration.[ADDRESS_201735]   urinalysis  results performed  at local lab, within 7 days of visit, for dipstick and microscopic  for pH, bilirubin, blood, nitrate, protein, 
specific gravity, glucose, ketones, RBC/HPF,   WBC/HPF,  urobilinogen,  leukocyte  esterase  